Citadel Advisors
FATE icon

Citadel Advisors’s Fate Therapeutics FATE Stock Holding History

Citadel Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.1K Sell
10,400
-16,900
-62% -$31.3K ﹤0.01% 13318
2026
Q1 		$32.8K Sell
27,300
-5,900
-18% -$7.18K ﹤0.01% 12545
2025
Q4 		$32.6K Buy
33,200
+15,700
+90% +$18.9K ﹤0.01% 12200
2025
Q3 		$22.1K Buy
17,500
+4,100
+31% +$4.42K ﹤0.01% 12476
2025
Q2 		$15K Buy
13,400
+8,000
+148% +$9.3K ﹤0.01% 12158
2025
Q1 		$4.27K Sell
5,400
-10,500
-66% -$12.9K ﹤0.01% 13904
2024
Q4 		$26.2K Buy
15,900
+6,900
+77% +$17.4K ﹤0.01% 12988
2024
Q3 		$31.5K Sell
9,000
-5,000
-36% -$19.5K ﹤0.01% 12388
2024
Q2 		$45.9K Buy
14,000
+4,400
+46% +$19.3K ﹤0.01% 11857
2024
Q1 		$70.5K Sell
9,600
-1,200
-11% -$7.43K ﹤0.01% 11814
2023
Q4 		$40.4K Buy
10,800
+2,000
+23% +$4.72K ﹤0.01% 12002
2023
Q3 		$18.7K Sell
8,800
-13,600
-61% -$45.1K ﹤0.01% 12682
2023
Q2 		$107K Sell
22,400
-3,400
-13% -$18.8K ﹤0.01% 10841
2023
Q1 		$147K Sell
25,800
-4,600
-15% -$27.8K ﹤0.01% 10669
2022
Q4 		$307K Buy
30,400
+17,600
+138% +$331K ﹤0.01% 9268
2022
Q3 		$287K Sell
12,800
-100
-0.8% -$2.89K ﹤0.01% 9675
2022
Q2 		$320K Sell
12,900
-8,300
-39% -$229K ﹤0.01% 9662
2022
Q1 		$822K Buy
21,200
+2,100
+11% +$81.3K ﹤0.01% 8158
2021
Q4 		$1.12M Sell
19,100
-1,700
-8% -$96.4K ﹤0.01% 7684
2021
Q3 		$1.23M Buy
20,800
+3,300
+19% +$259K ﹤0.01% 7598
2021
Q2 		$1.52M Sell
17,500
-11,200
-39% -$903K ﹤0.01% 7288
2021
Q1 		$2.37M Buy
28,700
+800
+3% +$76.7K ﹤0.01% 6007
2020
Q4 		$2.54M Sell
27,900
-1,900
-6% -$118K ﹤0.01% 4862
2020
Q3 		$1.19M Buy
29,800
+5,200
+21% +$182K ﹤0.01% 5713
2020
Q2 		$844K Buy
24,600
+6,000
+32% +$179K ﹤0.01% 6145
2020
Q1 		$413K Sell
18,600
-12,100
-39% -$306K ﹤0.01% 6769
2019
Q4 		$601K Buy
+30,700
New +$488K ﹤0.01% 6511
2019
Q2 		– Sell
-19,400
Closed -$341K – 9358
2019
Q1 		$341K Buy
19,400
+300
+2% +$4.74K ﹤0.01% 7421
2018
Q4 		$245K Buy
+19,100
New +$266K ﹤0.01% 7580

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's FATE Position: Q2 2026 in Review

Citadel Advisors increased its Fate Therapeutics (FATE) stake by 5.3% in Q2 2026, buying an estimated $93.2K and bringing the position to 993,308 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #5911.

Citadel Advisors first reported a position in FATE in Q4 2015 and has held it in 35 quarters since. The position peaked at $112M in Q2 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Citadel Advisors held 993,308 shares of Fate Therapeutics worth $2.68M as of Q2 2026.
  • Citadel Advisors bought 50,382 Fate Therapeutics shares in Q2 2026, an estimated $93.2K.
  • Fate Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5911 holding.
  • Citadel Advisors first reported a position in Fate Therapeutics in Q4 2015 and has held it in 35 quarters since.
  • Citadel Advisors's Fate Therapeutics position peaked at $112M in Q2 2020.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.